Report
EUR 85.33
For Business Accounts Only
MicroPort MedBot (MM) is a surgical robot company which designs, develops and commercializes surgical robots to assist surgeons in performing complex surgical procedures. It is the only company with a product portfolio covering the five major and fast-growing surgical specialties of laparoscopic, orthopedic, panvascular, natural orifice and percutaneous surgical procedures, as per Frost & Sullivan (F&S).
Its flagship products, Toumai Laparoscopic Surgical Robot, DFVision 3D Electronic Laparoscope and Honghu Orthopedic Surgical Robot, have all been admitted to the NMPA’s Green Path. Toumai and Honghu are at or near the registration approval stage, and DFVision has recently received NMPA approval.
We have looked at the company’s background and products in our earlier notes, MicroPort MedBot Pre-IPO - RoboDoc - pre-revenue, has a large competitor but a large market as well and MicroPort MedBot Pre-IPO - RoboDoc - PHIP updates and a look at its Largest competitor.
In this note, we will talk about valuations.
MicroPort MedBot Pre-IPO
Shanghai MicroPort MedBot Group (MM), a surgical robot company, aims to raise up to US$1bn in its Hong Kong IPO.MicroPort MedBot (MM) is a surgical robot company which designs, develops and commercializes surgical robots to assist surgeons in performing complex surgical procedures. It is the only company with a product portfolio covering the five major and fast-growing surgical specialties of laparoscopic, orthopedic, panvascular, natural orifice and percutaneous surgical procedures, as per Frost & Sullivan (F&S).
Its flagship products, Toumai Laparoscopic Surgical Robot, DFVision 3D Electronic Laparoscope and Honghu Orthopedic Surgical Robot, have all been admitted to the NMPA’s Green Path. Toumai and Honghu are at or near the registration approval stage, and DFVision has recently received NMPA approval.
We have looked at the company’s background and products in our earlier notes, MicroPort MedBot Pre-IPO - RoboDoc - pre-revenue, has a large competitor but a large market as well and MicroPort MedBot Pre-IPO - RoboDoc - PHIP updates and a look at its Largest competitor.
In this note, we will talk about valuations.
Underlyings
MicroPort Scientific Corp
SHANGHAI MICROPORT MEDBOT GR
SHANGHAI MICROPORT MEDICAL G
Provider
Aequitas Research
Aequitas Research is a leading ECM research firm with a focus on IPOs and placements/follow-on offerings across the Asia Pacific with deal size of over USD100m.
Since 2015, we have covered 400+ IPOs and 450+ placements with a hit rate of 73% and 65%, respectively. We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic analysis.
Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis. We also provide a more quant driven analysis on placement/follow-on offerings.
Markets that we cover include:
Hong Kong,
China ADRs,
India,
Japan,
Australia, and
ASEAN.
Hong Kong,
China ADRs,
India,
Japan,
Australia, and
ASEAN.
Sumeet Singh
Other Reports on these Companies
Other Reports from Aequitas Research
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.